Lipid mediators of inflammation as novel plasma biomarkers to identify patients with bacteremia

Journal of Infection

Volumn 70, Issue 5, 2015, Pages 433-444

  To, Kelvin K W ^a,b   Lee, Kim Chung ^b   Wong, Samson S Y ^a,b   Lo, Ka Ching ^b   Lui, Yin Ming ^b   Jahan, Akhee S ^b   Wu, Andrea L ^b   Ke, Yi Hong ^b   Law, Chun Yiu ^b   Sze, Kong Hung ^b   Lau, Susanna K P ^a,b   Woo, Patrick C Y ^a,b   Lam, Ching Wan ^b   Yuen, Kwok Yung ^a,b  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Bacteremia; Biomarker; Lipid; Metabolomic; Organic acid; Plasma

Indexed keywords

2,3,4 TRIMETHOXYCINNAMATE; ACYLCARNITINE; BIOLOGICAL MARKER; CINNAMIC ACID; FATTY ACID ESTER; GLYCEROPHOSPHORYLCHOLINE; LIPID; SPHINGOLIPID; UNCLASSIFIED DRUG; AUTACOID; CARNITINE; FATTY ACID;

ADULT; AGED; ARTICLE; BACTEREMIA; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; INFLAMMATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLITE; METABOLOMICS; NONHUMAN; PLASMA; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VERY ELDERLY; ANALOGS AND DERIVATIVES; BLOOD; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOLATION AND PURIFICATION; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; BIOMARKERS; CARNITINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FATTY ACIDS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LIPIDS; MALE; METABOLOMICS; MIDDLE AGED; PROGNOSIS; ROC CURVE; SPHINGOLIPIDS;

EID: 84927004125     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2015.02.011     Document Type: Article

References (37)

1. To K.K., Lo W.U., Chan J.F., Tse H., Cheng V.C., Ho P.L. Clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity. Int J Infect Dis 2013 Feb, 17(2):e120-e124.
2. Coburn B., Morris A.M., Tomlinson G., Detsky A.S. Does this adult patient with suspected bacteremia require blood cultures?. JAMA 2012 Aug 1, 308(5):502-511.
3. Goto M., Al-Hasan M.N. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin Microbiol Infect 2013 Jun, 19(6):501-509.
4. Chung V.Y., Tai C.K., Fan C.W., Tang C.N. Severe acute pyelonephritis: a review of clinical outcome and risk factors for mortality. Hong Kong Med J 2014 Aug, 20(4):285-289. 10.12809/hkmj134061.
5. Kim K.S., Kim K., Jo Y.H., Kim T.Y., Lee J.H., Lee S.J., et al. A simple model to predict bacteremia in women with acute pyelonephritis. J Infect 2011 Aug, 63(2):124-130.
6. Henriquez-Camacho C., Losa J. Biomarkers for sepsis. BioMed Res Int 2014, 2014:547818.
7. Woo P.C., Lam C.W., Tam E.W., Leung C.K., Wong S.S., Lau S.K., et al. First discovery of two polyketide synthase genes for mitorubrinic acid and mitorubrinol yellow pigment biosynthesis and implications in virulence of Penicillium marneffei. PLoS Negl Trop Dis 2012, 6(10):e1871.
8. To K.K., Fung A.M., Teng J.L., Curreem S.O., Lee K.C., Yuen K.Y., et al. Characterization of a Tsukamurella pseudo-outbreak by phenotypic tests, 16S rRNA sequencing, pulsed-field gel electrophoresis, and metabolic footprinting. J Clin Microbiol 2013 Jan, 51(1):334-338.
9. Lau S.K., Tang B.S., Teng J.L., Chan T.M., Curreem S.O., Fan R.Y., et al. Matrix-assisted laser desorption ionisation time-of-flight mass spectrometry for identification of clinically significant bacteria that are difficult to identify in clinical laboratories. J Clin Pathol 2014 Apr, 67(4):361-366.
10. Chen J.H., Yam W.C., Ngan A.H., Fung A.M., Woo W.L., Yan M.K., et al. Advantages of using matrix-assisted laser desorption ionization-time of flight mass spectrometry as a rapid diagnostic tool for identification of yeasts and mycobacteria in the clinical microbiological laboratory. J Clin Microbiol 2013 Dec, 51(12):3981-3987.
11. Seymour C.W., Yende S., Scott M.J., Pribis J., Mohney R.P., Bell L.N., et al. Metabolomics in pneumonia and sepsis: an analysis of the GenIMS cohort study. Intensive Care Med 2013 Aug, 39(8):1423-1434.
12. Laiakis E.C., Morris G.A., Fornace A.J., Howie S.R. Metabolomic analysis in severe childhood pneumonia in the Gambia, West Africa: findings from a pilot study. PLoS One 2010, 5(9).
13. Lam C.W., Law C.Y., To K.K., Cheung S.K., Lee K.C., Sze K.H., et al. NMR-based metabolomic urinalysis: a rapid screening test for urinary tract infection. Clin Chim Acta 2014 Sep 25, 436:217-223.
14. Yamanaka G., Ishii C., Kawashima H., Oana S., Miyajima T., Hoshika A. Cerebrospinal fluid Diacron-Reactive Oxygen Metabolite levels in pediatric patients with central nervous system diseases. Pediatr Neurol 2008 Aug, 39(2):80-84.
15. Langley R.J., Tsalik E.L., van Velkinburgh J.C., Glickman S.W., Rice B.J., Wang C., et al. An integrated clinico-metabolomic model improves prediction of death in sepsis. Sci Transl Med 2013 Jul 24, 5(195):195ra95.
16. Lakshmanan V., Rhee K.Y., Wang W., Yu Y., Khafizov K., Fiser A., et al. Metabolomic analysis of patient plasma yields evidence of plant-like alpha-linolenic acid metabolism in Plasmodium falciparum. J Infect Dis 2012 Jul 15, 206(2):238-248.
17. Weiner J., Parida S.K., Maertzdorf J., Black G.F., Repsilber D., Telaar A., et al. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS One 2012, 7(7):e40221.
18. Cui L., Lee Y.H., Kumar Y., Xu F., Lu K., Ooi E.E., et al. Serum metabolome and lipidome changes in adult patients with primary dengue infection. PLoS Negl Trop Dis 2013, 7(8):e2373.
19. Chandrasekar P.H., Brown W.J. Clinical issues of blood cultures. Arch Intern Med 1994 Apr 25, 154(8):841-849.
20. Kirn T.J., Weinstein M.P. Update on blood cultures: how to obtain, process, report, and interpret. Clin Microbiol Infect 2013 Jun, 19(6):513-520.
21. Woo P.C., Lam C.W., Tam E.W., Lee K.C., Yung K.K., Leung C.K., et al. The biosynthetic pathway for a thousand-year-old natural food colorant and citrinin in Penicillium marneffei. Sci Rep 2014, 4:6728.
22. Lin S.H., Lai C.C., Tan C.K., Liao W.H., Hsueh P.R. Outcomes of hospitalized patients with bacteraemic and non-bacteraemic community-acquired pneumonia caused by Streptococcus pneumoniae. Epidemiol Infect 2011 Sep, 139(9):1307-1316.
23. Loonen A.J., Wolffs P.F., Bruggeman C.A., van den Brule A.J. Developments for improved diagnosis of bacterial bloodstream infections. Eur J Clin Microbiol Infect Dis 2014 Oct, 33(10):1687-1702. 10.1007/s10096-014-2153-4.
24. Fedson D.S. Treating influenza with statins and other immunomodulatory agents. Antivir Res 2013 Sep, 99(3):417-435.
25. Zheng B.J., Chan K.W., Lin Y.P., Zhao G.Y., Chan C., Zhang H.J., et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2008 Jun 10, 105(23):8091-8096.
26. Tam V.C., Quehenberger O., Oshansky C.M., Suen R., Armando A.M., Treuting P.M., et al. Lipidomic profiling of influenza infection identifies mediators that induce and resolve inflammation. Cell 2013 Jul 3, 154(1):213-227.
27. Maceyka M., Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature 2014 Jun 5, 510(7503):58-67.
28. Favory R., Lancel S., Marchetti P., Mordon S., Chopin C., Formstecher P., et al. Endotoxin-induced myocardial dysfunction: evidence for a role of sphingosine production. Crit Care Med 2004 Feb, 32(2):495-501.
29. Teijaro J.R., Walsh K.B., Cahalan S., Fremgen D.M., Roberts E., Scott F., et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 2011 Sep 16, 146(6):980-991.
30. Paumen M.B., Ishida Y., Muramatsu M., Yamamoto M., Honjo T. Inhibition of carnitine palmitoyltransferase I augments sphingolipid synthesis and palmitate-induced apoptosis. J Biol Chem 1997 Feb 7, 272(6):3324-3329.
31. Puskarich M.A., Kline J.A., Krabill V., Claremont H., Jones A.E. Preliminary safety and efficacy of L-carnitine infusion for the treatment of vasopressor-dependent septic shock: a randomized control trial. JPEN J Parenter Enter Nutr 2013 Jul 12, 38(6):736-743.
32. Corr P.B., Creer M.H., Yamada K.A., Saffitz J.E., Sobel B.E. Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. J Clin Invest 1989 Mar, 83(3):927-936.
33. Hirota K. Involvement of hypoxia-inducible factors in the dysregulation of oxygen homeostasis in sepsis. Cardiovasc Hematol Disord Drug Targets 2015, 15(1):29-40.
34. Reuter S.E., Evans A.M. Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. Clin Pharmacokinet 2012 Sep 1, 51(9):553-572.
35. Mihalik S.J., Goodpaster B.H., Kelley D.E., Chace D.H., Vockley J., Toledo F.G., et al. Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity 2010 Sep, 18(9):1695-1700.
36. Kumar S., Arya P., Mukherjee C., Singh B.K., Singh N., Parmar V.S., et al. Novel aromatic ester from Piper longum and its analogues inhibit expression of cell adhesion molecules on endothelial cells. Biochemistry 2005 Dec 6, 44(48):15944-15952.
37. Petti C.A., Bhally H.S., Weinstein M.P., Joho K., Wakefield T., Reller L.B., et al. Utility of extended blood culture incubation for isolation of Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, and Kingella organisms: a retrospective multicenter evaluation. J Clin Microbiol 2006 Jan, 44(1):257-259.